AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1780996
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) (3 mg/kg for one day, then 6 mg/kg daily for 12 d)
Trial: 7174860
Drug: Metoclopramide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (40 mg)
Trial: 7174860
Drug: Metoclopramide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (60 mg)
Trial: 8842603
Drug: Glimepiride 4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 4 mg
Trial: 20300631
Drug: Local standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local standard of care (immunological and clinical criteria for treatment failure, discretionary VL testing)
Trial: 11926713
Drug: Flurbiprofen 8.75
RxNorm normalized name: flurbiprofen 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 8.75 mg lozenge with concomitant antibiotics
Trial: 8082521
Drug: Ultralente insulin
RxNorm normalized name: ultralente insulin, beef
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralente insulin (Humulin U)
Trial: 8082521
Drug: Intermediate insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate insulin (Humulin I)
Trial: 2554837
Drug: Pindolol 15
RxNorm normalized name: pindolol 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 15 mg/day (beta-blocker)
Trial: 27055279
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion (0.26 μg/kg/h)
Trial: 27055279
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion (2.0 μg/kg/h)
Trial: 25151916
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (PE plus sertraline)
Trial: 20348496
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg primaquine daily for 7 days
Trial: 20348496
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg primaquine daily for 7 days
Trial: 9011483
Drug: Two years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two years of IFN therapy
Trial: 9011483
Drug: Continuing IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing IFN therapy for at least 12 months
Trial: 9011483
Drug: Initial IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial IFN treatment courses of 24 months
Trial: 7961557
Drug: Clozapine concentration
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine concentration > 420 ng/mL
Trial: 7961557
Drug: Clozapine concentration
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine concentration < 420 ng/mL
Trial: 7961557
Drug: Clozapine concentration
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine concentration > 420 ng/mL at Week 12
Trial: 7961557
Drug: Clozapine concentration
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine concentration < 420 ng/mL at Week 12
Trial: 26771267
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone (0.5 mg/kg in 5 mL saline)
Trial: 26771267
Drug: Control (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5 mL IV saline)
Trial: 21755811
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops)
Trial: 21755811
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops)
Trial: 16430342
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg BID and Routine care
Trial: 6311392
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with cyclophosphamide (1.5 g/m2 days 1‐3), 4‐dimethyl epipodophylloxtin (200 mg/m2 days 1‐3), vincristine (1.5 mg/m2 days 1 and 3), and Adriamycin (80 mg/m2 day 1)
Trial: 6311392
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy without Adriamycin
Trial: 6311392
Drug: Prophylactic brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic brain irradiation (3000 rad) and 4 courses of usual doses of the same drugs
Trial: 28498636
Drug: Preoperative bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative bowel stimulation via the distal limb of the loop ileostomy using an 18Fr Foley catheter and infusing with 500 ml of normal saline mixed with 30 g of a thickening agent (Nestle© Thicken‐Up©), performed 10 times over 3 weeks before ileostomy closure.
Trial: 21252171
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD)
Trial: 21252171
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg LD/150 mg MD
Trial: 25653574
Drug: Fondaparinux 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 1.5 mg once daily
Trial: 23819225
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of western medicine
Trial: 11558009
Drug: Intercostal Nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal Nerve Block (ICB) with Bupivacaine (BUP) 3 mg/kg 0.5 % with epinephrine 1 : 200 000
Trial: 11558009
Drug: Meperidine 1
RxNorm normalized name: meperidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 1 mg/kg administered i.v.
Trial: 9626638
Drug: PTH (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH (400 IU/day subcutaneous human PTH (1-34)) + alendronate (10 mg/day)
Trial: 9626638
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/day) alone
Trial: 2646848
Drug: Intravenous bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bupivacaine 0.5% 20 ml with adrenaline (5 micrograms/ml) administered through an indwelling intrapleural catheter at 4-hour intervals four times daily for 2 days.
Trial: 2646848
Drug: Intramuscular oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular oxycodone on request (control group).
Trial: 1101615
Drug: etidocaine 1%
RxNorm normalized name: etidocaine 1% preservative-free injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etidocaine 1% with adrenaline 5 mug/ml
Trial: 1108582
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% with adrenaline 5 mug/ml
Trial: 10773182
Drug: Antidepressant agents
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant agents
Trial: 9483814
Drug: Paracervical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical anaesthesia (2 x 10 ml 0.5% Bupivacain solution)
Trial: 8416441
Drug: Zoladex (goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex (goserelin 3.6 mg) implant every 4 weeks plus estradiol valerate, 2 mg/day, with norethisterone 5 mg from days 22-28
Trial: 8416441
Drug: Zoladex (goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex (goserelin 3.6 mg) implant every 4 weeks plus placebo ERT tablets daily
Trial: 8416441
Drug: Placebo implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo implant every 4 weeks plus placebo ERT tablets daily
Trial: 3792432
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 10 mg ketanserin
Trial: 3792432
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 10 mg ketanserin
Trial: 3792432
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 20 mg ketanserin
Trial: 3792432
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 40 mg ketanserin
Trial: 3792432
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 60 mg ketanserin
Trial: 18782439
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg sCT with 50 ml of water
Trial: 18782439
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg sCT with 50 ml of water taken 30 and 60 minutes prior to meal time
Trial: 15940460
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg erythromycin
Trial: 15940460
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg erythromycin
Trial: 10071275
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg, 2-hour intravenous infusion every 4 weeks for 24 cycles)
Trial: 10071275
Drug: Placebo (2-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2-hour intravenous infusion every 4 weeks for 24 cycles)
Trial: 7564371
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD (once-daily controlled-delivery)
Trial: 7564371
Drug: Diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem SR (twice-daily sustained-release)
Trial: 28540844
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 200 μg
Trial: 28540844
Drug: FS MDPI
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS MDPI 200/12.5 μg
Trial: 28540844
Drug: Fp HFA
RxNorm normalized name: FP-1096
DrugBank: FP-1096 (DB05310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp HFA 440 μg
Trial: 28540844
Drug: FS DPI
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS DPI 500/50 μg
Trial: 28540844
Drug: All Fp
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All Fp MDPI doses
Trial: 28540844
Drug: All FS
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All FS MDPI doses
Trial: 25839338
Drug: Shakuyaku-Kanzo-to (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shakuyaku-Kanzo-to (7.5 g/d)
Trial: 25839338
Drug: Biperiden (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden (3 mg/d)
Trial: 24004620
Drug: Prolonged use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged use of aspirin before tooth extraction (observation group I)
Trial: 24004620
Drug: Prolonged use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged use of aspirin before tooth extraction (observation group II)
Trial: 24004620
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin before tooth extraction (control group I)
Trial: 24004620
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin before tooth extraction (control group II)
Trial: 5082545
Drug: Metolazone (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metolazone (doses ranging from 20-150 mg)
Trial: 23469947
Drug: Plasma g-tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma g-tocopherol
Trial: 21510895
Drug: Methylphenidate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.5 mg/kg in divided b.i.d. dose)
Trial: 6389142
Drug: Chronic antidysrhythmic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic antidysrhythmic treatment (specific agents not mentioned)
Trial: 6389142
Drug: Control (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (not specified, but implied to be no treatment or placebo)
Trial: 6389142
Drug: Chronic antidysrhythmic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic antidysrhythmic treatment
Trial: 26597179
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg daily for 3 days
Trial: 26597179
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from Rivaroxaban 20 mg daily to Edoxaban 60 mg
Trial: 26597179
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from Dabigatran Etexilate 150 mg twice daily to Edoxaban 60 mg
Trial: 27536427
Drug: MLK 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLK 10mg (7-day administration)
Trial: 27536427
Drug: MLK 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLK 10mg (3-day administration)
Trial: 27536427
Drug: MLK 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLK 10mg (1-day administration)
Trial: 12925048
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg od
Trial: 12925048
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg od
Trial: 10843301
Drug: Alcohol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (dose sufficient to raise blood alcohol level to .08)
Trial: 8076052
Drug: Conventional non-operative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non-operative treatment
Trial: 3987178
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg every 6 hours by mouth)
Trial: 3987178
Drug: Ranitidine (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (160 mg every 12 hours by mouth)
Trial: 24712335
Drug: Telephonic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephonic medication therapy management (MTM) intervention
Trial: 25614280
Drug: Mipomersen 200
RxNorm normalized name: mipomersen 200 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 200 mg weekly subcutaneous
Trial: 19127911
Drug: General regulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General regulation acupuncture and cupping therapy (warming needle moxibustion, plum-blossom needle, moving cupping, retaining the cup), thrice each week for 3 months
Trial: 12808177
Drug: Daytime dwell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime dwell with 1100 ml/m2 icodextrin solution for one week (week 2)
Trial: 10584283
Drug: Preseasonal short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preseasonal short-term immunotherapy
Trial: 8738859
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion (8.12 mmol/day, group A, n = 81)
Trial: 8738859
Drug: Potassium infusion
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium infusion (10.49 mmol/day, group B, n = 77)
Trial: 8738859
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose solution (group C, n = 87)
Trial: 8738859
Drug: Placebo (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2% dextrose solution, group D, n = 81)
Trial: 6339293
Drug: Halometasone/triclosan cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halometasone/triclosan cream
Trial: 6339293
Drug: Nerisona C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerisona C cream
Trial: 24549596
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment (1,000 mg/day)
Trial: 21049734
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation containing kojic acid, emblica extract, and glycolic acid
Trial: 18201437
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg daily)
Trial: 10200006
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg daily)
Trial: 12037372
Drug: Elmex toothpaste
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elmex toothpaste for unsupervised home use daily and Elmex gel for use once a week
Trial: 12037372
Drug: Elmex toothpaste
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elmex toothpaste and placebo gel
Trial: 12037372
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual oral care habits)
Trial: 7897151
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg with cimetidine 600 mg every 12 hours for 10 days
Trial: 7897151
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg with cimetidine 600 mg every 12 hours for 10 days
Trial: 2650604
Drug: Rectal endosonography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal endosonography (ES)
Trial: 23843020
Drug: Conference calls
RxNorm normalized name: miconazole nitrate Topical Cream [Clearly Confident]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conference calls (CC)
Trial: 17699310
Drug: Omacor 4-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor 4-g dosage
Trial: 17699310
Drug: Omacor 8-g
RxNorm normalized name: patiromer
DrugBank: Patiromer (DB09263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor 8-g dosage
Trial: 26804646
Drug: JNJ‐40411813 (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐40411813 (50mg to 150 mg b.i.d, flexibly dosed)
Trial: 24521953
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing (20 mg/kg)
Trial: 24521953
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (1 g)
Trial: 22172554
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (1 g per day as choline bitartrate)
Trial: 15780099
Drug: Sirolimus combined
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus combined with low-dose calcineurin inhibitors
Trial: 18054611
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) therapy
Trial: 9687101
Drug: Amoxycillin (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (5, 7.5, or 10 mg/kg)
Trial: 9687101
Drug: Amoxycillin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (any dose)
Trial: 9687101
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (2.5, 5, 7.5, or 10 mg/kg)
Trial: 9687101
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (2.5, 5, 7.5, or 10 mg/kg)
Trial: 9687101
Drug: Amoxycillin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (oral doses)
Trial: 9687101
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (oral doses)
Trial: 9687101
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (oral doses)
Trial: 22383630
Drug: Oral pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pioglitazone (PIO) 15 mg once daily for 12 weeks
Trial: 15030738
Drug: Docetaxel in
RxNorm normalized name: docetaxel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel in combination with cisplatin (DP)
Trial: 12171669
Drug: Initial syphilis
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial syphilis screening using rapid plasma reagin or Venereal Disease Research Laboratory tests, confirmed by fluorescent treponemal antibody absorption.